The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey
Open accessAbstract
The development of drug-induced lupus remains a matter of concern in patients treated with anti-tumour necrosis factor (TNF) alpha. The incidence of such adverse effects is unknown. We undertook a retrospective national study to analyse such patients. Between June and October 2003, 866 rheumatology and internal medicine practitioners from all French hospital centres prescribing anti-TNF in rheumatic diseases registered on the website of the 'Club Rhumatismes et Inflammation' were contacted by email to obtain the files of patients with TNF-induced systemic lupus erythematosus. Twenty-two cases were collected, revealing two aspects of these manifestations. Ten patients (six patients receiving infliximab, four patients receiving etanercept) only had anti-DNA antibodies and skin manifestations one could classify as 'limited skin lupus' or 'toxidermia' in a context of autoimmunity, whereas 12 patients (nine patients receiving infliximab, three patients receiving etanercept) had more complete drug-induced lupus with systemic manifestations and at least four American Congress of Rheumatology criteria. One patient had central nervous system manifestations. No patients had lupus nephritis. The signs of lupus occurred within a mean of 9 months (range 3–16 months) in patients treated with infliximab and within a mean of 4 months (range 2–5 months) in patients treated with etanercept. In all cases after diagnosis was determined, anti-TNF was stopped and specific treatment introduced in eight patients: two patients received intravenous methylprednisolone, four patients received oral steroids (15–35 mg/day), and two patients received topical steroids. Lupus manifestations abated within a few weeks (median 8 weeks, standard deviation 3–16) in all patients except one with longer-lasting evolution (6 months). At that time, cautious estimations (unpublished data from Schering Plough Inc. and Wyeth Inc.) indicated that about 7700 patients had been exposed to infliximab and 3000 to etanercept for inflammatory arthritides in France. It thus appears that no drug was more implicated than the other in lupus syndromes, whose incidence was 15/7700 = 0.19% with infliximab and 7/3800 = 0.18% with etanercept. Clinicians should be aware that lupus syndromes with systemic manifestations may occur in patients under anti-TNF alpha treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
(2016) · Diagnostic Imaging: Brain · doi:10.1016/b978-0-323-37754-6.50094-4 · Cited by 3,990
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
Drug-induced systemic lupus erythematosus associated with etanercept therapy
Shakoor, N., Michalska, M., Harris, C. A., & Block, J. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07714-0 · Cited by 458
De Rycke, L., Kruithof, E., Van Damme, N., Hoffman, I. E. A., Van den Bossche, N., Van den Bosch, F., Veys, E. M., & De Keyser, F. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10876 · Cited by 223
Anti-TNF-?-induced systemic lupus syndrome
Debandt, M., Vittecoq, O., Descamps, V., Lo�t, X. L., & Meyer, O. (2003) · Clinical Rheumatology · doi:10.1007/s10067-002-0654-5 · Cited by 189
Self-citationIn Vivo Neutralization of TNF-α Promotes Humoral Autoimmunity by Preventing the Induction of CTL
Via, C. S., Shustov, A. R., Rus, V., Lang, T., Nguyen, P., & Finkelman, F. D. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.12.6821 · Cited by 151
Adverse Skin Reactions to Anti-TNF-Alpha Monoclonal Antibody Therapy
Devos, S. A., van den Bossche, N., Vos, M. D., & Naeyaert, J. M. (2003) · Dermatology · doi:10.1159/000069965 · Cited by 147
Jonsdottir, T., Forslid, J., van Vollenhoven, A., Harju, A., Brannemark, S., Klareskog, L., & van Vollenhoven, R. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.018093 · Cited by 109
Etanercept: therapeutic use in patients with rheumatoid arthritis
Garrison, L., & McDonnell, N. D. (1999) · Annals of the Rheumatic Diseases · doi:10.1136/ard.58.2008.i65 · Cited by 106
Cited by
Autoimmune Diseases Induced by TNF-Targeted Therapies: Analysis of 233 Cases
Ramos-Casals, M., Brito-Zerón, P., Muñoz, S., Soria, N., Galiana, D., Bertolaccini, L., Cuadrado, M.-J., & Khamashta, M. A. (2007) · Medicine · doi:10.1097/md.0b013e3181441a68 · Cited by 733
Psoriasis: Which therapy for which patient
Kaushik, S. B., & Lebwohl, M. G. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.06.057 · Cited by 368
de Gannes, G. C., Ghoreishi, M., Pope, J., Russell, A., Bell, D., Adams, S., Shojania, K., Martinka, M., & Dutz, J. P. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.2.223 · Cited by 325
Autoimmune diseases induced by biological agents
Ramos-Casals, M., Roberto-Perez-Alvarez, Diaz-Lagares, C., Cuadrado, M.-J., & Khamashta, M. A. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.10.003 · Cited by 323
Beigel, F., Schnitzler, F., Paul Laubender, R., Pfennig, S., Weidinger, M., Göke, B., Seiderer, J., Ochsenkühn, T., & Brand, S. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21362 · Cited by 84
Metadata
- Authors
- De Bandt, M., Sibilia, J., Le Loët, X., Prouzeau, S., Fautrel, B., Marcelli, C., Boucquillard, E., Siame, J. L., Mariette, X., & Inflammation, T. C. R. E.
- Venue
- Arthritis Research & Therapy
- Published
- 2005-03-01
- Volume
- 7
- Issue
- 3
- Pages
- R545-51
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W1518420099
- Cited by
- 401
- References
- 16
- FWCI
- 15.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.